Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 3147Neoplasms 2478Carcinoma, Non-Small-Cell Lung 1889Prostatic Neoplasms 1645Colorectal Neoplasms 1438Lung Neoplasms 1312Multiple Myeloma 940Neoplasm Metastasis 930Leukemia, Myeloid, Acute 885Pancreatic Neoplasms 862Ovarian Neoplasms 815Melanoma 794Carcinoma, Hepatocellular 745Stomach Neoplasms 650Brain Neoplasms 643Recurrence 642Squamous Cell Carcinoma of Head and Neck 639Head and Neck Neoplasms 613Glioblastoma 575Lymphoma 551Uterine Cervical Neoplasms 549Triple Negative Breast Neoplasms 515Precursor Cell Lymphoblastic Leukemia-Lymphoma 511Carcinoma, Renal Cell 505Endometrial Neoplasms 467Hematologic Neoplasms 466Urinary Bladder Neoplasms 462Colonic Neoplasms 448Sarcoma 439Lymphoma, Non-Hodgkin 439

Interventions

Specimen Handling 1Biopsy 13-aminopyridine-2-carboxaldehyde thiosemicarbazone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Serous Adenocarcinoma × 1 year × Clear all
NCT04494113 2026-05-13

Testing the Response to the Anti-cancer Drug, Triapine, in Uterine Cancers Using Markers From the Tissue at the Time of Hysterectomy

National Cancer Institute (NCI)

Phase EARLY_PHASE1 Active not recruiting
12 enrolled
Gynecologic

Endometrial Serous Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡